NPS Pharmaceuticals Inc (NPSP.OQ)

NPSP.OQ on NASDAQ Stock Exchange Global Select Market

26.59USD
4:00pm EDT
Price Change (% chg)

$-0.55 (-2.03%)
Prev Close
$27.14
Open
$27.20
Day's High
$27.38
Day's Low
$26.58
Volume
416,602
Avg. Vol
554,134
52-wk High
$39.67
52-wk Low
$21.60

NPSP.OQ

Chart for NPSP.OQ

About

NPS Pharmaceuticals, Inc. (NPS) is a biopharmaceutical company focused on pioneering and delivering therapies that transform the lives of patients with rare diseases worldwide. The Company’s primary product Gattex 0.05 mg/kg/d (teduglutide [rDNA origin]) for injection, for subcutaneous use was approved by the United States Food... (more)

Overall

Beta: 0.80
Market Cap (Mil.): $2,892.08
Shares Outstanding (Mil.): 106.56
Dividend: --
Yield (%): --

Financials

  NPSP.OQ Industry Sector
P/E (TTM): 1,397.53 146.41 33.29
EPS (TTM): 0.02 -- --
ROI: 0.86 -3.28 17.33
ROE: 1.96 -7.94 18.19
Search Stocks

U.S. FDA panel recommends approval of NPS hormone replacement drug

- A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted 8-5 to recommend approval for Natpara, a hormone replacement therapy developed by NPS Pharmaceuticals Inc.

12 Sep 2014

U.S. FDA panel recommends approval of NPS hormone replacement drug

Sept 12 - A panel of outside advisers to the U.S. Food and Drug Administration on Friday voted 8-5 to recommend approval for Natpara, a hormone replacement therapy developed by NPS Pharmaceuticals Inc.

12 Sep 2014

FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though data from one trial site was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

10 Sep 2014

FDA staff: NPS drug effective; no significant safety imbalance

WASHINGTON, Sept 10 - NPS Pharmaceuticals Inc's hormone replacement therapy Natpara reduced the need for calcium and vitamin D supplements in clinical trials, though data from one trial site was excluded due to manufacturing violations, according to a preliminary review by the U.S. Food and Drug Administration.

10 Sep 2014

Shire secures $5 billion funding for NPS Pharma bid: The Times

- London-listed drugmaker Shire Plc has secured a $5 billion credit facility for a takeover offer for New-Jersey-based NPS Pharmaceuticals, The Times of London reported on Sunday.

01 Jun 2014

Shire considering bid for NPS Pharmaceuticals - FT

LONDON, May 30 - London-listed drugmaker Shire is considering a bid for New Jersey-based NPS Pharmaceuticals, FT Alphaville reported on Friday citing sources.

30 May 2014

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider: Thomson Reuters Stock Report
$25.00
Provider: New Constructs, LLC
$25.00
Provider: Stock Traders Daily
$20.00
Provider: S&P Capital IQ – STARS Reports
$127.00
Provider: Reuters Investment Profile
$20.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.

Search Stocks